CD24 and triple-negative breast carcinoma: We have shown that compound 1 lowers CSC, CD44+CD24+, and CD44− subpopulations and expression of CD15s in CD44+CD24+ and CD44− cells, showing that it or similar analogues could be developed into new treatments for triple-negative breast cancer.